This is the third leg of the comparison triangle, and it is the most lopsided of the three. NAD+ versus NR is not a close call for the same reason NAD+ versus NMN is not: you cannot efficiently swallow the finished coenzyme, so the contest is between a precursor and a detour.
The one-paragraph version
NR is a small, uncharged precursor two enzymatic steps from NAD+, with the longest clean regulatory record in the US supplement market. Oral NAD+ is a large charged dinucleotide that is largely dismantled before absorption — arriving, in effect, as precursors anyway. Between a precursor you chose and a precursor you got by accident, choose the first.
Why this comparison resolves quickly
The NAD vs NMN page covers the absorption argument in full, and it applies identically here, so the short version will do.
NAD+ is a dinucleotide: two nucleotides bridged by phosphate. It is large by the standards of things that cross the intestinal wall intact, and it carries charge. What appears to happen to an oral dose is progressive breakdown in the digestive tract into smaller fragments, which are absorbed as the precursors they have become.
NR is the smallest and simplest of the common precursors: nicotinamide riboside, a nicotinamide attached to a ribose sugar, uncharged and unphosphorylated. Those properties are exactly the ones that favour absorption and membrane crossing.
The route each takes
NR → NMN → NAD+
NR converts to NMN via an enzyme called NRK, then NMN to NAD+ via NMNAT. Two steps, both well described, neither obviously a bottleneck at supplemental doses.
Oral NAD+ has no comparable clean diagram, which is the point. Its path depends on where and how completely it is broken down, which varies between people and between meals.
Side by side
| Oral NAD+ | NR | |
|---|---|---|
| What it is | The finished coenzyme | Precursor, two steps out |
| Size & charge | Dinucleotide, charged | Small, uncharged |
| Absorbed intact | Largely no | Favourable profile |
| Cell entry | Not the relevant question | Less contested than NMN |
| US supplement status | Sold as a supplement | Long-standing accepted NDI notifications |
| Dose transparency | Poor | Good |
| Human research depth | Thin | The deepest of the precursors |
Where NR's real argument lies
Against oral NAD+, NR wins on mechanism. Its more interesting case is the regulatory one.
NR has had accepted New Dietary Ingredient notifications on file for years and has been continuously available in the US. It never went through the exclusion period that removed NMN from shelves between 2022 and the FDA's reversal on 29 September 2025. If you want the precursor with the least complicated paperwork behind it, that is NR, and it is a legitimate reason to choose it.
The counterweight is cost. NR's best-known form is a branded ingredient with a dominant supplier, and it generally prices higher per milligram than NMN. You are paying something for that cleaner record.
The claim to watch for
Products in this category are sometimes marketed on containing "real NAD+" rather than "just a precursor." Stated as chemistry rather than copy, that is a description of a less efficient delivery route sold as an upgrade. The finished coenzyme in a capsule is not closer to your cells than a precursor is; it is further, because it has to be taken apart first.
Related: NAD vs NMN · NMN vs NR · Why NAD+ declines